- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05009446
Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM (SNMM)
A Prospective Single Arm Clinical Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced Sinonasal Malignant Melanoma
Sinonasal mucosal melanoma (SNMM) is a very rare tumor, and SNMM is highly aggressive in nature, with a 5-year survival rate of about 20~30%. Most patients underwent local recurrence and distant metastasis within one or two years of treatment.
There is no unified standard for the treatment of SNMM.The principle of treatment for surgically resectable stage T3 and partial T4 SNMM is complete resection of the primary tumor, combined with postoperative radiotherapy. While locally unresectable SNMM has a poorer prognosis, lower incidence, fewer clinical data have been reported.
This study will explore the role of preoperative radiotherapy and chemotherapy in improving the 2-year OS rate, loco-regional control rate and distant metastasis rate.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Anticipato)
Fase
- Prima fase 1
Contatti e Sedi
Contatto studio
- Nome: Xiaole Song, MD
- Numero di telefono: 15821388769
- Email: jxfxsxl@163.com
Luoghi di studio
-
-
Shanghai
-
Shanghai, Shanghai, Cina, 200031
- Reclutamento
- Eye& ENT Hospital, Fudan University
-
Contatto:
- Weifang Wang
- Numero di telefono: 13916229507
-
Sub-investigatore:
- Xiaoshen Wang, MD,PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age over 18 years old;
- Pathologically confirmed with sinonasal mucosal melanoma;
- Eligible for assessment by enhanced contrast computed tomography scan or magnetic Resonance Imaging (MRI);
- T4N0-1M0 according to the 8th edition American Joint Committee on Cancer (AJCC) staging system, and breaks through the natural anatomical boundaries of orbital fascia or dura mater; or 2) any Tumor stage, with retropharyngeal node metastasis. unresectable tumor after multi-disciplinary team (MDT) discussion.
- Eastern Cooperative Oncology Group (ECOG) score between 0 to 2;
- No distant metastasis;
- Adequate organ function;
- Sign the informed consent forms.
Exclusion Criteria:
- There is evidence or suspicious of distant metastasis on clinical examination or imaging examination;
- suffered from uncontrolled concurrent diseases that may interfere with treatment;
- Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.);
- With surgical contraindications: severe cardiopulmonary disease, coagulation dysfunction, etc;
- With and conditions that interfere with patient compliance or safety;
- With severe mental or neurological diseases;
- Uncontrolled active infection diseases;
- Pregnant or breastfeeding women;
- Patients without personal freedom or independent civil capacity;
- Other situations that are not suitable.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Preoperative radiotherapy and chemotherapy
Preoperative radiotherapy and chemotherapy plus endoscopic surgery
|
endoscopic surgery or endoscope-assisted surgery open surgery
radiotherapy was administrated before surgery
Chemotherapy was administrated before surgery.
Chemotherapy may also be administrated after surgery in selected cases.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Overall survival
Lasso di tempo: From date of first treatment until the date of death from any cause,through study completion,up to 2 years.
|
2 year Overall Survival rate
|
From date of first treatment until the date of death from any cause,through study completion,up to 2 years.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Progression-free survival
Lasso di tempo: From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first,through study completion,up to2 years
|
the date of first treatment to the first recording of disease progression or death from any cause.
|
From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first,through study completion,up to2 years
|
Local progression free survival
Lasso di tempo: From date of first treatment to local failure or date of death from any cause,through study completion,up to 2 years
|
the date of first treatment to local failure or death
|
From date of first treatment to local failure or date of death from any cause,through study completion,up to 2 years
|
Regional progression free survival
Lasso di tempo: From date of first treatment to regional failure or date of death from any cause, through study completion,up to 2 years
|
the date of first treatment to regional failure or death
|
From date of first treatment to regional failure or date of death from any cause, through study completion,up to 2 years
|
Distant metastasis free survival
Lasso di tempo: From date of first treatment to distant metastasis or date of death from any cause, through study completion,up to 2 years
|
the date of first treatment to distant metastasis or death
|
From date of first treatment to distant metastasis or date of death from any cause, through study completion,up to 2 years
|
ORR
Lasso di tempo: From date of first treatment to the date of best overall response before surgery, assessed up to 6 months
|
objective remission rate
|
From date of first treatment to the date of best overall response before surgery, assessed up to 6 months
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Hongmeng Yu, MD,PhD, Eye& ENT Hospital of Fudan University, Shanghai, China
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SNMM-SA-RTNeo
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su endoscopic surgery
-
ARCAGY/ GINECO GROUPReclutamentoCancro ovarico stadio IIIC | Stadio del cancro ovarico IV | Cancro ovarico stadio IIIbFrancia
-
Mayo ClinicTerminatoReflusso gastroesofageo | Ernia, iatale | Sondaggi e questionari | FundoplicatioStati Uniti
-
Fudan UniversitySconosciuto
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... e altri collaboratoriCompletatoCancro ovarico | Cancro della tuba di Falloppio | Cancro della cavità peritonealeSpagna, Francia, Danimarca, Belgio, Germania, Austria, Cina, Italia, Corea, Repubblica di, Norvegia, Svezia, Regno Unito
-
Dr. Faruk SemizIscrizione su invito
-
National Cancer Centre, SingaporeCompletatoMalattie della tiroideSingapore
-
University of TriesteCompletato
-
Kocaeli Derince Education and Research HospitalKocaeli UniversitySconosciutoMiglioramento del recupero dopo l'intervento chirurgico | Chirurgia a cuore apertoTacchino
-
Assiut UniversityNon ancora reclutamentoMalattie esofagee | Complicanza di esofagostomia
-
University of Illinois at ChicagoEthicon Endo-SurgeryRitiratoMalattie del colon e del rettoStati Uniti